Takeaways Vertex’s suzetrigine filing is important because it could bring Canada its first new acute pain drug class in more than 20 years, which would give hospitals and payers a non-...
Takeaways Hims & Hers is using generic semaglutide to anchor its Canadian weight‑loss and metabolic program, giving it a priced‑in, recurring revenue product at about CAD 149/month that...
Takeaways Hemgenix has moved from theory to practice in Canada, with the first patient now treated outside a trial and public funding in place in Ontario and British Columbia. Market‑wise, this...
Takeaways Phoenix and Raven are turning Canada’s new generic semaglutide approvals into immediate, retail-like access, which will likely accelerate GLP‑1 uptake beyond traditional bric...
Takeaways Orimed’s expanded PrLuxa‑D line should make vitamin D supplementation more flexible in Canada by covering a much wider dose range, which helps physicians match treatment to defici...
Takeaways Thyconvi gives BioSyent a differentiated way into Canadian endocrinology by offering the first liquid levothyroxine, so it can compete on convenience and dosing flexibility r...
Takeaways Dr. Reddy’s is using this Canada launch to cement itself as an early global player in generic GLP‑1 injectables, showing it can move from approval to market in days and supply at ...
Takeaways Apo‑Semaglutide should put real downward pressure on Ozempic pricing in Canada and accelerate a shift of volume from the originator to generics, especially in publicly funded and emplo...
Takeaways: Felix is positioning itself as the price‑breaker in Canada’s GLP‑1 obesity market, using cheaper semaglutide (as generics arrive) to tackle the main dropout driver and convert strong ...
Takeaways: This authorization makes iStatis the first rapid point‑of‑care HBsAg test cleared in both Canada and North America, giving frontline providers a 15‑minute to...
